⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Optimization of Radiotherapy in Treatment of Painful Bone Metastasis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Optimization of Radiotherapy in Treatment of Painful Bone Metastasis

Official Title: Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis

Study ID: NCT00610272

Study Description

Brief Summary: Bone metastasis is one of the most frequent end complications of the cancer. Radiation therapy is the mainstay of treatment in this disease. Single fraction radiotherapy in both single and multiple bone metastasis is widely used, but optimization of the single dose fractionation is needed. Two different regimens of radiotherapy dose fractionation will be investigated in both single and multiple bone metastasis and endpoints will include pain relief as well as toxicity and quality of life.

Detailed Description: PROTOCOL SCHEMA Group A Treatment of single site of painful bone metastasis: Arm 1: 4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks Arm 2: 8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks Group B Treatment of multiple bone metastasis: lower hemibody radiotherapy (LHBI): Arm 3: 8 Gy in a single fraction; retreatments \> 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI); Arm 4: 12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments \> 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Centre Pierre et Marie Curie, Centre hospitalier universitaire Mustapha (CHU), Alger, , Algeria

Irmandade de Santa Casa de Misericordia de Porto Alegre, Porto Alegre, , Brazil

Misr Oncology Center (MOC), Cairo, , Egypt

Tata Memorial Hospital, Mumbai, , India

Institute of Oncology, University of Vilinius, Vilnius, , Lithuania

Institute of Radiotherapy and Oncology, Skopje, , Macedonia, The Former Yugoslav Republic of

Instituto Nacional de Cancerología (INCAN), Ciudad de Mexico, , Mexico

Institute of Oncology and Radiology, Belgrade, , Serbia

Hospital Clinic Universidad de Barcelona, Barcelona, , Spain

Hospital Son Dureta, Palma de Mallorca, , Spain

Institut national de cancer Salah Azaiz, Tunis, , Tunisia

Mount Vernon Cancer Centre, Northwood, , United Kingdom

Contact Details

Name: Elena Fidarova, MD

Affiliation: International Atomic Energy Agency

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: